- Research validates a strong association between ctDNA changes and cancer treatment outcomes.
- Study expands to include multiple solid tumor types with different treatment categories.
- Biodesix (BDSX, Financial) explores combining ctDNA with proteomics for advanced cancer monitoring.
Biodesix, Inc. (NASDAQ: BDSX), in collaboration with Bio-Rad Laboratories and Friends of Cancer Research, has contributed to groundbreaking research published in Clinical Cancer Research. The study provides significant evidence supporting the correlation between changes in circulating tumor DNA (ctDNA) and treatment outcomes for cancer patients. This research is part of the ctMoniTR Project, aimed at enhancing the use of ctDNA in monitoring treatment responses.
The second phase of the ctMoniTR Project, utilizing Bio-Rad's Droplet Digital™ PCR technology, broadens the analysis to encompass additional solid tumor types and treatment categories, such as those treated with tyrosine kinase inhibitors. These findings build upon previous studies focused on advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors.
Biodesix is keen on advancing cancer diagnostics by exploring the combination of ctDNA with proteomics to detect molecular residual disease (MRD). This innovative approach aims to identify minimal cancer cell presence post-treatment, providing valuable insights for clinical cancer care. The company's latest advancements in this area will be presented at the American Association for Cancer Research Annual Meeting on April 28, 2025.
